JERUSALEM--(BUSINESS WIRE)--Mar. 11, 2015--
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, today announced that it has
closed its previously announced underwritten public offering of
14,375,000 American Depositary Shares (“ADSs”), each representing ten
(10) of its Ordinary Shares, at a public offering price of $2.00 per
ADS, for gross proceeds of $28.75 million. All of the ADSs in the
offering were sold by BioLineRx. The amount of ADSs sold includes an
additional 1,875,000 ADSs purchased by the underwriters pursuant to the
over-allotment option granted to them by BioLineRx.
JMP Securities acted as sole book-running manager for the offering. Roth
Capital Partners acted as lead manager. Maxim Group LLC acted as
The ADSs were issued pursuant to a shelf registration statement that was
previously filed with, and declared effective by, the Securities and
Exchange Commission (SEC). A final prospectus supplement related to the
offering has been filed with the SEC and is available on the SEC's
website located at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by means of a
prospectus supplement and accompanying prospectus forming a part of the
effective registration statement, copies of which may be obtained, when
available, from JMP Securities LLC, 600 Montgomery Street, 10th Floor,
San Francisco, California 94111, Attention: Prospectus Department, or by
telephone: (415) 835-8985.
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a
pivotal CE-Mark registration trial scheduled for completion in mid-2015;
BL-8040, a cancer therapy platform, which is in the midst of a Phase 2
study for acute myeloid leukemia (AML) as well as a Phase 1 study for
stem cell mobilization; and BL-7010 for celiac disease, which has
successfully completed a Phase 1/2 study.
In December 2014, BioLineRx entered into a strategic collaboration with
Novartis for the co-development of selected Israeli-sourced novel drug
candidates. The companies intend to co-develop a number of pre-clinical
and early clinical therapeutic projects through clinical
proof-of-concept for potential future licensing by Novartis.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s SEC documents, press releases, and events.
BioLineRx’s IR app is available on the iTunes App Store as well as the
Google Play Store.
Various statements in this release concerning BioLineRx’s future
expectations constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include words such as “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future events.
These forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of BioLineRx to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new
products; and the ability to implement technological improvements. These
and other factors are more fully discussed in the “Risk Factors” section
of BioLineRx’s most recent annual report on Form 20-F filed with the
Securities and Exchange Commission on March 17, 2014. In addition, any
forward-looking statements represent BioLineRx’s views only as of the
date of this release and should not be relied upon as representing its
views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required by
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.